Acute Myocardial Infarction: Selection of Reperfusion Strategies in the Individual Patient

Summary

The selection of the reperfusion therapy (thrombolysis, PTCA, or no reperfusion) in acute myocardial infarction should depend on the riskbenefit ratio, the availability, and the costs. Thrombolysis is available everywhere and is the standard of reperfusion therapy, but carries the risk of intracranial haemorrhage. PTCA is more effective with less risk, but it is also more expensive and available only in specialised centres. In current clinical practise in Germany, the only important determinant for using PTCA as a reperfusion strategy is the availability of a catheter laboratory. Besides availabilty, the selection of reperfusion therapy should be made more on clinical relevance: (i) PTCA especially in patients with a large benefit, the presence of contraindications to thrombolysis, or in cardiogenic shock, and (ii) thrombolysis, if PTCA is not immediately available.

Key words

Thrombolysis - PTCA - risk-benefit - clinical practice

• References

• 1 Boersma H, van der Vlugt MJ, Arnold AER. et al. Estimated life gain expectancy. Eur Heart J 1996; 17: 64-75.
• 2 Fibrinolytic Therapy. Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-22.
• 3 Rustige J, Schiele R, Burczyk U, Koch A, Gottwik M, Neuhaus KL, Tebbe U, Uebis R. Senges for the ALKK study group: The 60-minutes-myocardial-infarction project – treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997; 18: 1438-46.
• 4 Schuster S, Koch A, Burczyk U, Schiele R, Wagner S, Zahn R, Glunz HG, Heinrich F, Stuby K, Berg G, Voigtlander T, Gieseler U, Jacob M, Hauptmann P. Senges J, fur die ALKK Studiengruppe: Fruhbehandlung des akuten Myokardinfarktes: Umsetzung von Therapierichtlinien in den klinischen Alltag, MITRA Pilotphase. Z Kardiol 1997; 86: 273-83.